Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMHPME3)

Drug Name
PMID18163548C4 Drug Info
Synonyms 7IN; 1vja; AC1L9MNX; GTPL6545; BDBM50231520; US8476306, 6.12
Indication
Disease Entry ICD 11 Status REF
Myocardial ischemia BA6Z Clinical trial [1]
Reperfusion injury ND56.Z Clinical trial [1]
Cross-matching ID
PubChem CID
449051
TTD Drug ID
DMHPME3

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Urokinase-type plasminogen activator (PLAU) TTGY7WI UROK_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Urokinase-type plasminogen activator (PLAU) DTT PLAU 5.352 5.741 6.924 6.898
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Myocardial ischemia
ICD Disease Classification BA6Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Urokinase-type plasminogen activator (PLAU) DTT PLAU 5.32E-70 1.07 1.82
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6.